A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation
Florence Beckerich(Université Paris-Est Créteil), Mauricette Michallet(Université Claude Bernard Lyon 1), Adriana Pleșa(Hospices Civils de Lyon), Jérémy Monfray(Hôpital Lyon Sud), Valérie Dubois(Établissement Français du Sang), Stéphane Morisset(Lyon 1 Université), Fiorenza Barraco(Hôpital Lyon Sud), Xavier Thomas(Hôpital Lyon Sud), Isabelle Tigaud(Inserm), Oriane Le Borgne(Hôpital Lyon Sud), Mohamad Sobh(Ottawa Hospital), Isabelle Mollet, Franck E. Nicolini(Hôpital Lyon Sud), Sophie Ducastelle(Hôpital Lyon Sud), Hélène Labussière(Hôpital Lyon Sud), Lila Gilis(Hospices Civils de Lyon)
Cited by 0
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547